Video
Dr. Barata stresses significance of tumor sequencing in urothelial carcinoma
Author(s):
“The real-world data suggest that the use of tumor sequencing is definitely suboptimal,” says Pedro C. Barata, MD, MSc.
Video Player is loading.
Pedro C. Barata, MD, MSc, an associate professor of Medicine in Hematology and Medical Oncology at the Tulane University School of Medicine, discusses the importance of tumor sequencing to the implementation of precision medicine for patients with urothelial carcinoma.
Related Videos
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
Dr. Vince on evaluation of prostate cancer polygenic risk scores
Related Content
